new glp-1 receptor agonists Agonist Services for Type 2 Diabetes and Obesity Drug Development PDB-101: Molecule of the Month:

Standard guidelines recommend bariatric surgery consultation for BMI 35+ regardless of comorbidities, BMI 30-34.9 with serious obesity-related conditions (Type 2 diabetes, hypertension, sleep apnea, severe joint disease), and specifically for BMI 30-35 with uncontrolled Type 2 diabetes despite medical management

In 2019, the estimated health care costs of obesity in the U.S

Lim J-H, Kwon S, Seo YJ, Kim YH, Kwon H, Kim YS, Lee H, Kim Y-L, Kim C-D, Park S-H, et al

Both medications are oral tablets used alongside diet and exercise, and both can be prescribed together for maximum glycemic benefit

doi: 10.1016/j.bone.2014.02.013